The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Cardiovascular Toxicities Associated With Ibrutinib
Open accessAbstract
BACKGROUND Ibrutinib has revolutionized treatment for several B-cell malignancies. However, a recent clinical trial where ibrutinib was used in a front-line setting showed increased mortality during treatment compared with conventional chemotherapy. Cardiovascular toxicities were suspected as the culprit but not directly assessed in the study. OBJECTIVES The purpose of this study was to identify and characterize cardiovascular adverse drug reactions (CV-ADR) associated with ibrutinib. METHODS This study utilized VigiBase (International pharmacovigilance database) and performed a disproportionality analysis using reporting odds ratios (ROR) and information component (IC) to determine whether CV-ADR and CV-ADR deaths were associated with ibrutinib. IC compares observed and expected values to find associations between drugs and adverse drug reactions using disproportionate Bayesian-reporting; IC025 (lower end of the IC 95% credibility interval) >0 is significant. RESULTS This study identified 303 ibrutinib-associated cardiovascular deaths. Ibrutinib was associated with higher reporting of supraventricular arrhythmias (SVAs) (ROR: 23.1; 95% confidence interval: 21.6 to 24.7; p < 0.0001; IC025: 3.97), central nervous system (CNS) hemorrhagic events (ROR: 3.7; 95% confidence interval: 3.4 to 4.1; p < 0.0001; IC025: 1.63), heart failure (ROR: 3.5; 95% confidence interval: 3.1 to 3.8; p < 0.0001; IC025: 1.46), ventricular arrhythmias (ROR: 4.7; 95% confidence interval: 3.7 to 5.9; p < 0.0001; IC025: 0.96), conduction disorders (ROR: 3.5; 95% confidence interval: 2.7 to 4.6; p < 0.0001; IC025: 0.76), CNS ischemic events (ROR: 2.2; 95% confidence interval: 2.0 to 2.5; p < 0.0001; IC025: 0.73), and hypertension (ROR: 1.7; 95% confidence interval: 1.5 to 1.9; p < 0.0001; IC025: 0.4). CV-ADR often occurred early after ibrutinib administration. Importantly, CV-ADR were associated with fatalities that ranged from ∼10% (SVAs and ventricular arrhythmias) to ∼20% (CNS events, heart failure, and conduction disorders). Ibrutinib-associated SVA portends poor prognosis when CNS events occur concomitantly, with 28.8% deaths (15 of 52 cases). CONCLUSIONS Severe and occasionally fatal cardiac events occur in patients exposed to ibrutinib. These events should be considered in patient care and in clinical trial designs. (Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents [EROCA]; NCT03530215).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N. L., Li, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509388 · Cited by 1,583
A Bayesian neural network method for adverse drug reaction signal generation
Bate, A., Lindquist, M., Edwards, I. R., Olsson, S., Orre, R., Lansner, A., & De Freitas, R. M. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050466 · Cited by 1,476
Salem, J.-E., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., Gobert, A., Spano, J.-P., Balko, J. M., Bonaca, M. P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30608-9 · Cited by 1,271
Self-citationThe reporting odds ratio and its advantages over the proportional reporting ratio
Rothman, K. J., Lanes, S., & Sacks, S. T. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1001 · Cited by 1,111
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Barr, P. M., Rogers, K. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1812836 · Cited by 962
Self-citationIbrutinib in Previously Treated Waldenström’s Macroglobulinemia
Treon, S. P., Tripsas, C. K., Meid, K., Warren, D., Varma, G., Green, R., Argyropoulos, K. V., Yang, G., Cao, Y., Xu, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501548 · Cited by 942
Cardiovascular Toxic Effects of Targeted Cancer Therapies
Moslehi, J. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1100265 · Cited by 635
Self-citationLong-term Outcomes in Individuals With Prolonged PR Interval or First-Degree Atrioventricular Block
Cheng, S. (2009) · JAMA · doi:10.1001/jama.2009.888 · Cited by 614
VigiBase, the WHO Global ICSR Database System: Basic Facts
Lindquist, M. (2008) · Drug Information Journal · doi:10.1177/009286150804200501 · Cited by 587
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
Miklos, D., Cutler, C. S., Arora, M., Waller, E. K., Jagasia, M., Pusic, I., Flowers, M. E., Logan, A. C., Nakamura, R., Blazar, B. R., et al. (2017) · Blood · doi:10.1182/blood-2017-07-793786 · Cited by 514
Dreyling, M., Jurczak, W., Jerkeman, M., Silva, R. S., Rusconi, C., Trneny, M., Offner, F., Caballero, D., Joao, C., Witzens-Harig, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00667-4 · Cited by 463
Leenhardt, A., Glaser, E., Burguera, M., Nürnberg, M., Maison-Blanche, P., & Coumel, P. (1994) · Circulation · doi:10.1161/01.cir.89.1.206 · Cited by 415
McMullen, J. R., Boey, E. J. H., Ooi, J. Y. Y., Seymour, J. F., Keating, M. J., & Tam, C. S. (2014) · Blood · doi:10.1182/blood-2014-10-604272 · Cited by 403
Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery
Norén, G. N., Hopstadius, J., & Bate, A. (2013) · Statistical Methods in Medical Research · doi:10.1177/0962280211403604 · Cited by 336
Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies
Shatzel, J. J., Olson, S. R., Tao, D. L., McCarty, O. J. T., Danilov, A. V., & DeLoughery, T. G. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13651 · Cited by 279
Brown, J. R., Moslehi, J., O’Brien, S., Ghia, P., Hillmen, P., Cymbalista, F., Shanafelt, T. D., Fraser, G., Rule, S., Kipps, T. J., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.171041 · Cited by 267
Self-citationAnti-HERG activity and the risk of drug-induced arrhythmias and sudden death
De Bruin, M. L., Pettersson, M., Meyboom, R. H. B., Hoes, A. W., & Leufkens, H. G. M. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi092 · Cited by 245
Brown, J. R., Hillmen, P., O’Brien, S., Barrientos, J. C., Reddy, N. M., Coutre, S. E., Tam, C. S., Mulligan, S. P., Jaeger, U., Barr, P. M., et al. (2018) · Leukemia · doi:10.1038/leu.2017.175 · Cited by 243
Self-citationThe risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
Leong, D. P., Caron, F., Hillis, C., Duan, A., Healey, J. S., Fraser, G., & Siegal, D. (2016) · Blood · doi:10.1182/blood-2016-05-712828 · Cited by 233
Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
Aoyagi, T., & Matsui, T. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796390976 · Cited by 213
Ventricular arrhythmias and sudden death in patients taking ibrutinib
Lampson, B. L., Yu, L., Glynn, R. J., Barrientos, J. C., Jacobsen, E. D., Banerji, V., Jones, J. A., Walewska, R., Savage, K. J., Michaud, G. F., et al. (2017) · Blood · doi:10.1182/blood-2016-10-742437 · Cited by 213
Self-citationIbrutinib-Associated Atrial Fibrillation
Ganatra, S., Sharma, A., Shah, S., Chaudhry, G. M., Martin, D. T., Neilan, T. G., Mahmood, S. S., Barac, A., Groarke, J. D., Hayek, S. S., et al. (2018) · JACC: Clinical Electrophysiology · doi:10.1016/j.jacep.2018.06.004 · Cited by 205
Self-citationPretorius, L., Du, X.-J., Woodcock, E. A., Kiriazis, H., Lin, R. C. Y., Marasco, S., Medcalf, R. L., Ming, Z., Head, G. A., Tan, J. W., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090126 · Cited by 187
Lipsky, A. H., Farooqui, M. Z. H., Tian, X., Martyr, S., Cullinane, A. M., Nghiem, K., Sun, C., Valdez, J., Niemann, C. U., Herman, S. E. M., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.126672 · Cited by 172
Wiczer, T. E., Levine, L. B., Brumbaugh, J., Coggins, J., Zhao, Q., Ruppert, A. S., Rogers, K., McCoy, A., Mousa, L., Guha, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009720 · Cited by 163
Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms
Alexandre, J., Moslehi, J. J., Bersell, K. R., Funck‐Brentano, C., Roden, D. M., & Salem, J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.009 · Cited by 157
Self-citationAtrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study
Thompson, P. A., Lévy, V., Tam, C. S. L., Al‐Nawakil, C., Goudot, F., Quinquenel, A., Ysebaert, L., Michallet, A., Dilhuydy, M., Neste, E. V. D., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14324 · Cited by 124
Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies
Guha, A., Derbala, M. H., Zhao, Q., Wiczer, T. E., Woyach, J. A., Byrd, J. C., Awan, F. T., & Addison, D. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.002 · Cited by 115
Influence of steroid hormones on ventricular repolarization
Salem, J., Alexandre, J., Bachelot, A., & Funck‐Brentano, C. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.07.005 · Cited by 101
Self-citationElectrophysiological mechanisms of long and short QT syndromes
Tse, G., Chan, Y. W. F., Keung, W., & Yan, B. P. (2016) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2016.11.006 · Cited by 101
Busygina, K., Jamasbi, J., Seiler, T., Deckmyn, H., Weber, C., Brandl, R., Lorenz, R. L., & Siess, W. (2018) · Blood · doi:10.1182/blood-2017-09-808808 · Cited by 97
Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth
Chen, J., Kinoshita, T., Sukbuntherng, J., Chang, B. Y., & Elias, L. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0923 · Cited by 95
Salem, J., Yang, T., Moslehi, J. J., Waintraub, X., Gandjbakhch, E., Bachelot, A., Hidden‐Lucet, F., Hulot, J., Knollmann, B. C., Lebrun‐Vignes, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040162 · Cited by 86
Self-citationO'Brien, S. M., Hillmen, P., Coutre, S. E., Barr, P. M., Fraser, G. A. M., Tedeschi, A., Burger, J. A., Dilhuydy, M., Heß, G., Moreno, C., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.06.016 · Cited by 84
β-Adrenergic induced SR Ca 2+ leak is mediated by an Epac-NOS pathway
Pereira, L., Bare, D. J., Galice, S., Shannon, T. R., & Bers, D. M. (2017) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2017.04.005 · Cited by 83
Complex Influence of Gonadotropins and Sex Steroid Hormones on QT Interval Duration
Abehsira, G., Bachelot, A., Badilini, F., Koehl, L., Lebot, M., Favet, C., Touraine, P. A., Funck‐Brentano, C., & Salem, J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1877 · Cited by 70
Self-citationProlonged PR Interval Predicts Clinical Recurrence of Atrial Fibrillation After Catheter Ablation
Park, J., Kim, T., Lee, J. S., Park, J. K., Uhm, J., Joung, B., Lee, M., & Pak, H. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001277 · Cited by 64
Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors
Grouthier, V., Lebrun‐Vignes, B., Glazer, A. M., Touraine, P. A., Funck‐Brentano, C., Pariente, A., Courtillot, C., Bachelot, A., Roden, D. M., Moslehi, J. J., et al. (2018) · Heart · doi:10.1136/heartjnl-2017-312934 · Cited by 56
Self-citationPharmacology and mechanisms of action of new oral anticoagulants
Salem, J., Sabouret, P. F., Funck‐Brentano, C., & Hulot, J. (2014) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12091 · Cited by 51
Self-citationSalem, J., Dureau, P., Bachelot, A., Germain, M., Voiriot, P., Lebourgeois, B., Trégouët, D., Hulot, J., & Funck‐Brentano, C. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2251 · Cited by 42
Self-citationTomcsányi, J., Nényei, Z., Mátrai, Z., & Bózsik, B. (2016) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2016.07.004 · Cited by 36
de Jong, J., Hellemans, P., Jiao, J. J., Huang, Y., Mesens, S., Sukbuntherng, J., & Ouellet, D. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3471-x · Cited by 29
Wallace, N., Wong, E. Y.-M., COOPER, D. L., & Chao, H. H. (2016) · Clinical Case Reports · doi:10.1002/ccr3.719 · Cited by 28
Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System
Cheng, C., Woronow, D. I., Nayernama, A., Wroblewski, T., & Jones, S. C. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1457149 · Cited by 26
Ibrutinib-related bleeding: pathogenesis, clinical implications and management
Aguilar, C. (2018) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000749 · Cited by 26
A Perfect Storm: Tyrosine Kinase Inhibitor-Associated Polymorphic Ventricular Tachycardia
Beyer, A. B., Ganti, B. R., Majkrzak, A. A., et al. (2016) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2016.10.019 · Cited by 20
Profound Sinoatrial Arrest Associated with Ibrutinib
Mathur, K., Saini, A., Ellenbogen, K. A., & Shepard, R. K. (2017) · Case Reports in Oncological Medicine · doi:10.1155/2017/7304021 · Cited by 11
Investigating the Genetic Architecture of the PR Interval Using Clinical Phenotypes
Mosley, J. D., Shoemaker, M. B., Wells, Q. S., Darbar, D., Shaffer, C. M., Edwards, T. L., Bastarache, L. A., McCarty, C. A., Thompson, W. K., Chute, C. G., et al. (2017) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.116.001482 · Cited by 9
Self-citationSalem, J., Dureau, P., Funck‐Brentano, C., Hulot, J., El-Aissaoui, M., Aïssaoui, N., Urien, S., & Faisy, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.06.004 · Cited by 6
Self-citation
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Self-citationByrd, J. C., Hillmen, P., Ghia, P., Kater, A. P., Chanan-Khan, A., Furman, R. R., O'Brien, S., Yenerel, M. N., Illés, A., Kay, N., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01210 · Cited by 669
Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Self-citationChronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Hallek, M., & Al‐Sawaf, O. (2021) · American Journal of Hematology · doi:10.1002/ajh.26367 · Cited by 393
Metadata
- Authors
- Salem, J.-E., Manouchehri, A., Bretagne, M., Lebrun-Vignes, B., Groarke, J. D., Johnson, D. B., Yang, T., Reddy, N. M., Funck-Brentano, C., Brown, J. R., Roden, D. M., & Moslehi, J. J.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 74
- Issue
- 13
- Pages
- 1667-1678
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2976280418
- Cited by
- 266
- References
- 52
- FWCI
- 14.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.